The clinical trial registration ACTRN12625001083482 marks the first clinical evaluation of an intravenous Deciparticle formulation of everolimus, an established mTOR inhibitor used in treating breast cancer and other malignancies. The study is currently enrolling patients with advanced HR+/HER2– breast cancer or other mTOR-sensitive tumors at leading oncology centers across Australia through collaboration with SOCRU, Ingenū, and Medicilon.
Dr. Vuong Trieu, CEO of Sapu Nano and Oncotelic, emphasized the significance of this development, stating that Sapu-003 represents a substantial advance in the delivery of mTOR-targeted therapies. The partnerships established for this trial aim to accelerate development and bring this next-generation treatment to patients with advanced cancers who have limited therapeutic options.
The trial announcement was formally presented at the 8th Australian Translational Breast Cancer Research Symposium (ATBCR 2025), where Sapu Nano displayed its poster detailing the Sapu-003 formulation and study design. This presentation provided the oncology research community with crucial insights into the novel drug delivery technology being evaluated.
For additional information about Oncotelic Therapeutics, investors and interested parties can access the company's newsroom at https://ibn.fm/OTLC. The broader context of biomedical developments and communications in this sector can be explored through resources available at https://www.BioMedWire.com, which provides comprehensive coverage of biotechnology and life sciences advancements.
The development of intravenous Deciparticle technology addresses significant challenges in cancer treatment delivery, potentially offering improved bioavailability and targeted action compared to existing formulations. This advancement could have substantial implications for patients with advanced cancers who have developed resistance to current therapies or who require more effective treatment options with better safety profiles.
The successful development of Sapu-003 could transform the treatment landscape for mTOR-sensitive tumors, providing clinicians with new tools to combat aggressive cancers. The international collaboration involved in this trial demonstrates the global nature of cancer research and the importance of partnerships in advancing innovative therapeutic approaches that may benefit patients worldwide.
